Does Lopinavir And Ritonavir Interact with Erlotinib?
CDI records a major classification for Lopinavir And Ritonavir and Erlotinib. The stored summary is: Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable. The mechanism involves cyp3a4 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Lopinavir And Ritonavir Class
- Protease Inhibitor
- Erlotinib Class
- Kinase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Lopinavir And Ritonavir and your doctor is considering prescribing Erlotinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider